Xavier Montalban

MD, PhD

Scientist, Li Ka Shing Knowledge Institute

Research Programs

Biography

Dr. Xavier Montalban is an internationally recognized neurologist who is considered a key opinion leader within the field of multiple sclerosis (MS). Dr. Montalban has held diverse leadership positions and is currently a Professor of Medicine and Director of the Neurology Department at the University of Toronto. He also serves as Chair of the Department of Neurology-Neuroimmunology and Director of the Multiple Sclerosis Centre of Catalonia at the Vall d’Hebron University Hospital in Barcelona, Spain. The Multiple Sclerosis Centre of Catalonia, or Cemcat, is accredited as a national flagship service for the MS care process within the context of the Flagship Centres, Units, and Services programme of the Spanish Ministry of Health. Dr. Montalban is a former president of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and recently co-directed the development of the first Multiple Sclerosis Treatment Guidelines for ECTRIMS and the European Academy of Neurology. He has contributed more than 500 publications and several book chapters to the academic arena, served on multiple steering committees of clinical trials related to multiple sclerosis, and is a valued member of the International Panel on Multiple Sclerosis Diagnostic Criteria and Clinical Trials. With more than 25 years of research, Dr. Montalban continues to strive to discover more effective therapies for patients with MS and has brought paradigm shifts to the way we understand and treat MS.

Recent Publications

  1. Cohen, JA, Comi, G, Arnold, DL, Bar-Or, A, Selmaj, KW, Steinman, L et al.. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Mult. Scler. 2018; :1352458518789884. doi: 10.1177/1352458518789884. PubMed PMID:30043658 .
  2. Saposnik, G, Tobler, PN, Caceres, F, Terzaghi, MA, Ruff, C, Maurino, J et al.. Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. Front Neurol. 2018;9 :522. doi: 10.3389/fneur.2018.00522. PubMed PMID:30042720 PubMed Central PMC6048250.
  3. Montalban, X, Leist, TP, Cohen, BA, Moses, H, Campbell, J, Hicking, C et al.. Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018;5 (5):e477. doi: 10.1212/NXI.0000000000000477. PubMed PMID:30027104 PubMed Central PMC6047834.
  4. Leussink, VI, Montalban, X, Hartung, HP. Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. CNS Drugs. 2018; :. doi: 10.1007/s40263-018-0536-2. PubMed PMID:29992409 .
  5. Fissolo, N, Cervera-Carles, L, Villar Guimerans, LM, Lleó, A, Clarimón, J, Drulovic, J et al.. Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Mult. Scler. 2018; :1352458518786055. doi: 10.1177/1352458518786055. PubMed PMID:29985092 .
  6. Quintana, E, Coll, C, Salavedra-Pont, J, Muñoz-San Martín, M, Robles-Cedeño, R, Tomàs-Roig, J et al.. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. Eur. J. Neurol. 2018; :. doi: 10.1111/ene.13687. PubMed PMID:29797629 .
  7. Mulero, P, Midaglia, L, Montalban, X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018;11 :1756286418773025. doi: 10.1177/1756286418773025. PubMed PMID:29774057 PubMed Central PMC5952271.
  8. Marrie, RA, Montalban, X. Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night. Mult. Scler. 2018;24 (5):558-562. doi: 10.1177/1352458518767323. PubMed PMID:29692224 .
  9. Saposnik, G, Montalban, X. Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care. Front Neurol. 2018;9 :174. doi: 10.3389/fneur.2018.00174. PubMed PMID:29615967 PubMed Central PMC5869922.
  10. Kappos, L, Bar-Or, A, Cree, BAC, Fox, RJ, Giovannoni, G, Gold, R et al.. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391 (10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. PubMed PMID:29576505 .
Search PubMed

Affiliations & Other Activities

  • The Waugh Family Chair in Multiple Sclerosis Research, St. Michael’s Hospital
  • Medical Director, the BARLO MS Centre, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Division Director, Department of Neurology, University of Toronto
  • Director, Centre d’Esclerosi Múltiple de Catalunya (Cemcat)
X